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Abstract
In randomized clinical trials, adjustments for baseline covariates at both design
and analysis stages are highly encouraged by regulatory agencies. A recent trend
is to use a model-assisted approach for covariate adjustment to gain credibility and
efficiency while producing asymptotically valid inference even when the model is in-
correct. In this article we present three principles for model-assisted inference in
simple or covariate-adaptive randomized trials: (1) guaranteed efficiency gain princi-
ple, a model-assisted method should often gain but never hurt efficiency; (2) validity
and universality principle, a valid procedure should be universally applicable to all
commonly used randomization schemes; (3) robust standard error principle, variance
estimation should be heteroscedasticity-robust. To fulfill these principles, we recom-
mend a working model that includes all covariates utilized in randomization and all
treatment-by-covariate interaction terms. Our conclusions are based on asymptotic
theory with a generality that has not appeared in the literature, as most existing
results are about linear contrasts of outcomes rather than the joint distribution and
most existing inference results under covariate-adaptive randomization are special
cases of our theory. Our theory also reveals distinct results between cases of two
arms and multiple arms.
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Consider a clinical trial for assessing the causal effects from giving k treatments. Patients
in a sample for the trial are randomized into the k treatment arms according to fixed
proportions. Let Y (t) be a discrete or continuous potential response from a patient under
treatment t (we assume each patient in the trial receives one and only one treatment). Let
θ be the k-dimensional vector whose tth component is θt = E(Y
(t)), the unknown mean
potential response under treatment t, where E denotes population expectation. Based on
data collected from the trial, we would like to make statistical inference on given functions
of θ, such as a linear contrast θt−θs, a ratio θt/θs, or an odds ratio {θt/(1−θt)}/{θs/(1−θs)}
between two treatment arms t and s.
In clinical trials, we typically observe some baseline covariates for each patient, which
are measured prior to treatment assignments and, hence, are not affected by the treatment.
As emphasized in regulatory agency guidelines, the baseline covariates can be utilized in
the following two ways. (i) In the design stage, covariate-adaptive randomization can be
used to enforce the balancedness of treatments across levels of Z whose components are
discrete baseline prognostic factors, such as institution, disease stage, prior treatment,
gender, and age group. “Balance of treatment groups with respect to one or more specific
prognostic covariates can enhance the credibility of the results of the trial” (EMA, 2015).
(ii) In the analysis stage, a vector X of baseline covariates can be used to gain efficiency.
“Incorporating prognostic factors in the primary statistical analysis of clinical trial data can
result in a more efficient use of data to demonstrate and quantify the effects of treatment”
(FDA, 2019). More specifically, the investigator is advised to identify “the covariates
expected to have an important influence on the primary outcome” and to specify “how to
account for them in the analysis in order to improve precision and to compensate for any
lack of balance between groups” (ICH E9 (R1), 2019).
The well known analysis of variance (ANOVA) provides asymptotically valid inference
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on functions of θ for either discrete or continuous Y (t) when simple randomization is used,
i.e., patient treatment assignments are randomized independently. However, ANOVA does
not utilize the baseline covariates and can be inefficient.
An alternative is to model the dependence of Y on a baseline covariate vector X for
efficiency gain. However, such a model-based approach is unreliable because the inference
may be invalid if the model is misspecified (EMA, 2015). In practice, it is often hard to
specify the correct model or test any lack of fit. For this reason, a great deal of effort has
been made to develop model-assisted approaches that gain efficiency by utilizing covariates
in a working model and produce asymptotically valid inference even when the working
model is misspecified. Development of covariate adjustment methods is encouraged by
the most recent guidance for COVID-19: “To improve the precision of treatment effect
estimation and inference, sponsors should ... propose methods of covariate adjustment”
(FDA, 2020).
One example of the model-assisted approach is the analysis of covariance (ANCOVA)
which is widely recognized by researchers and regulatory agencies (EMA, 2015; FDA, 2019).
The working model used by the customary ANCOVA, originally proposed by Fisher (1935),
does not include treatment-by-covariate interaction terms (§2.3) and, thus, it is referred
to as the homogeneous working model. In fact, treatment-by-covariate interaction terms
are often ignored or even discouraged because of two perceptions: (i) even if the working
model is misspecified, ANCOVA can still provide valid inference as it is model-assisted; (ii)
a model without interaction terms have fewer coefficients to estimate and may have better
finite sample properties. However, these perceptions only provide a partial picture. When
the treatment effect is indeed heterogeneous, the ANCOVA estimator of θ without includ-
ing treatment-by-covariate interaction in its working model may be even less efficient than
the ANOVA estimator that uses no model assistance at all (Freedman, 2008; Lin, 2013).
The confusion about how ANCOVA should be implemented can be seen from recent con-
3
flicting recommendations by regulatory agencies: “The primary model should not include
treatment by covariate interactions.” (EMA, 2015); “The prespecified primary model can
include interaction terms if appropriate” and “The closer the model approximates the true
relationship between the outcome and the covariates, the greater the improvement in the
power of significance tests and the precision of estimates...” (FDA, 2019).
This leads to the first of our three principles presented in this article:
Principle 1 (Guaranteed efficiency gain). The working model should be chosen so that
the model-assisted estimator often gains but never loses efficiency when compared to a
benchmark estimator that does not adjust for any covariate.
Throughout this paper, the benchmark estimator is ANOVA. To fulfill Principle 1,
we recommend a heterogeneous working model for ANCOVA that includes treatment-by-
covariate interaction terms. We call this approach ANalysis of HEterogeneous COVAriance
(ANHECOVA) to distinguish from ANCOVA that specifically refers to ANCOVA using the
homogeneous working model. Our recommendation is motivated by the theoretical results
in earlier work (Cassel et al., 1976; Lin, 2013; Liu and Yang, 2020; Li and Ding, 2020, among
others), which we extend in §3.2-§3.3 to covariate-adaptive randomization and multiple
treatment arms. We show that the ANHECOVA estimator of θ is consistent, asymptotically
normal, and asymptotically more efficient than the ANCOVA estimator or the benchmark
ANOVA estimator; in fact, it is asymptotically the most efficient estimator within a class of
model-assisted estimators. In §3.1 we offer explanations of why the heterogeneous working
model is generally preferable over the homogeneous working model.
A concern for adding treatment-by-covariate interaction terms in a working model is
that the model may contain too many parameters and, hence, the finite sample performance
of the resulting asymptotically efficient inference procedure may be worse than that from
a model without interaction terms. For example, EMA (2015) recommends a compact
working model with “no more than a few covariates”. To address this issue, in §3.1 we
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develop a variant of ANHECOVA that improves its finite sample performance by using a
pooled estimator of the covariance matrix of baseline covariate used in working model.
Covariate-adaptive randomization has been widely adopted in modern clinical trials.
According to a recent review of nearly 300 clinical trials published in 2009 and 2014, 237
of them used covariate-adaptive randomization (Ciolino et al., 2019). Unlike simple ran-
domization, covariate-adaptive randomization generates a dependent sequence of treatment
assignments. Hence, conventional inference procedures constructed based on simple ran-
domization are not necessarily valid under covariate-adaptive randomization (EMA, 2015).
However, conventional methods are often applied in practice even when covariate-adaptive
randomization is used. Starting from Shao et al. (2010), various methods have been pro-
posed for valid inference, which in general requires the randomization scheme to have a
well-understood property (Shao and Yu, 2013; Ye, 2018; Bugni et al., 2018). However, two
limitations persist: (i) it is yet unclear how to obtain valid inference under complicated
randomization schemes such as Pocock-Simon’s minimization (Taves, 1974; Pocock and
Simon, 1975; EMA, 2015); (ii) the standard error formula for inference varies with the ran-
domization scheme and often has to be derived and proven under each particular scheme,
which is a nuisance to the practice. These motivate our second principle.
Principle 2 (Validity and universality). The model-assisted inference should be asymptot-
ically valid and can be universally applied to all commonly used randomization schemes.
In addition to validity, the universality means that a unified procedure can be used under
all commonly used randomization schemes, including covariate-adaptive randomization and
simple randomization. Our asymptotic theory in §3.3-3.4 shows that ANHECOVA achieves
this principle as its asymptotic variance is invariant to the randomization scheme, as long
as the randomization scheme satisfies a very mild condition (C2) stated in §2.2. However,
this appealing property is not shared by ANCOVA. First, the asymptotic normality of the
ANCOVA estimator of θ requires an additional condition (C3) on randomization, which is
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not satisfied by the popular Pocock-Simon’s minimization method. Second, the asymptotic
variance of the ANCOVA estimator varies with the randomization scheme.
Our third principle concerns robust variance estimation for asymptotically normally
distributed estimators of functions of θ, another crucial step for inference.
Principle 3 (Robust standard error). The model-assisted inference should use robust stan-
dard errors that account for heteroscedasticity.
The asymptotic theory for heteroscedasticity-robust standard errors was developed
decades ago (Huber, 1967; White, 1980) and has been widely used in econometrics. Alarm-
ingly, its usage in clinical trials is scarce. This is particularly relevant for model-assisted
inference because heteroscedasticity may arise from incorrect working models. Further-
more, the robust standard error also needs to take into account of the centering of baseline
covariates before fitting working models, which is needed to identify the mean potential
responses. Thus standard formulas for heteroscedasticity-robust standard errors do not
directly apply to model-assisted inference for clinical trials.
The conclusions we draw in this paper are based on a new theoretical result on the joint
asymptotic distribution of a class of covariate-adjusted estimators for θ, under simple or
covariate-adaptive randomization. Our new result is quite general and subsumes previous
results (mostly on the linear contrast θt− θs) as special cases (Shao et al., 2010; Lin, 2013;
Bugni et al., 2018, 2019). Furthermore, our theory offers new insights on when ANCOVA
may gain or lose efficiency over ANOVA. For example, under simple randomization with
two treatment arms, Lin (2013) showed that ANCOVA with homogeneous working model
satisfies Principle 1 (guaranteed efficiency gain over ANOVA) if the treatment allocation
is balanced. However, our theory shows that this does not extend to trials with more than
two arms, and is thus a peculiar property.
After introducing the notation, basic assumptions, and working models in §2, we present
the methodology and theory in §3. Some numerical results are given in §4. The paper is
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concluded with recommendations and discussions for clinical trial practice in §5. Technical
proofs can be found in the supplementary material.
2 Trial Design and Working Models
2.1 Sample
Recall that Y (t) represents the potential response under treatment t, t = 1, . . . , k. We use Z
to denote the vector of discrete baseline covariates used in covariate-adaptive randomization
and X to denote the vector of baseline covariates used in model-assisted inference. The
vectors Z and X are allowed to share the same entries.
Suppose that a random sample of n patients is obtained from the population under inves-
tigation. For the ith patient, let Y
(1)
i , ..., Y
(k)
i , Zi, and Xi be the realizations of Y
(1), ..., Y (k),
Z, and X, respectively. We impose the following mild condition.
(C1) (Y
(1)
i , . . . , Y
(k)
i , Zi, Xi), i = 1, . . . , n, are independent and identically distributed with
finite second order moments. The distribution of baseline covariates is not affected
by treatment and the covariance matrix ΣX = var(Xi) is positive definite.
Notice that no model between the potential responses and baseline covariates is assumed
in (C1), and the potential responses can be either discrete or continuous.
2.2 Treatment assignments
Let pi1, . . . , pik be the pre-specified treatment assignment proportions, 0 < pit < 1, and∑k
t=1 pit = 1. Let Ai be the k-dimensional treatment indicator vector that equals at if
patient i receives treatment t, where at denotes the k-dimensional vector whose tth com-
ponent is 1 and other components are 0. For patient i, the treatment Ai is assigned after
baseline covariates Zi and Xi are observed; only one treatment is assigned according to
Ai. The observed response is Yi = Y
(t)
i if and only if Ai = at. Once the treatments are
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assigned and the responses are recorded, the statistical inference is based on the observed
(Yi, Zi, Xi, Ai) for i = 1, ..., n.
The simple randomization scheme assigns patients to treatments completely at random,
under which the Ai’s are independent of the (Y
(1)
i , ..., Y
(k)
i , Xi)’s and are independent and
identically distributed with P (Ai = at) = pit, t = 1, ..., k. It does not make use of covariates
and, hence, may yield sample sizes that substantially deviate from the target assignment
proportions across levels of the prognostic factors.
To improve the credibility of the trial, it is often desirable to enforce the targeted treat-
ment assignment proportions across levels of Z by using covariate-adaptive randomization.
The three most popular covariate-adaptive randomization schemes are the stratified per-
muted block (Zelen, 1974), the stratified biased coin (Shao et al., 2010; Kuznetsova and
Johnson, 2017), both of which use all joint levels of Z as strata, and Pocock-Simon’s min-
imization (Taves, 1974; Pocock and Simon, 1975; Han et al., 2009), which aims to enforce
treatment assignment proportions across marginal levels of Z.
All these covariate-adaptive randomization schemes, as well as the simple randomiza-
tion, satisfy the following mild condition (Baldi Antognini and Zagoraiou, 2015).
(C2) The discrete covariate Z used in randomization has finitely many joint levels in Z and
satisfies (i) given {Zi, i = 1, . . . , n}, {Ai, i = 1, . . . , n} is conditionally independent
of {(Y (1)i , ..., Y (k)i , Xi), i = 1, . . . , n}; (ii) as n → ∞, nt(z)/n(z) → pit almost surely,
where n(z) is the number of patients with Z = z and nt(z) is the number of patients
with Z = z and treatment t, z ∈ Z, t = 1, ..., k.
2.3 Working models
The benchmark ANOVA approach does not model how the potential responses Y
(1)
i , ..., Y
(k)
i
depend on the baseline covariates Xi. It is based on
E(Yi | Ai) = ϑTAi, (1)
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where ϑ is a k-dimensional unknown vector and cT denotes the row vector that is the
transpose of a column vector c. By Lemma 2 in the supplementary material, ϑ identifies
θ = (θ1, ..., θk)
T , where θt = E(Y
(t)) is the mean potential response under treatment
t. In the classical exact ANOVA inference, the responses are assumed to have normal
distributions. So a common perception is that ANOVA can only be used for continuous
responses. As normality is not necessary in the asymptotic theory, the ANOVA and the
other approaches introduced next can be used for non-normal or even discrete responses
when n is large.
To utilize the baseline covariates, ANCOVA is based on the following homogeneous
working model,
E(Yi | Ai, Xi) = ϑTAi + β/T (Xi − µX), (2)
where ϑ and β/ are unknown vectors having the same dimensions as A and X, respectively,
and µX = E(Xi). There is no treatment-by-covariate interaction terms in (2), which
is incorrect if patients with different covariates benefit differently from receiving the same
treatment, a scenario that often occurs in clinical trials. By Lemma 2 in the supplementary
material, E{Yi−ϑTAi−β/T (Xi−µX)}2 is minimized at (ϑ, β/) = (θ, β), where β =
∑k
t=1 pitβt




i ). Thus, the ANCOVA estimator with working model (2) is model-
assisted (Theorems 1 and 3 in §3). Then, what is the impact of ignoring the treatment-
by-covariate interaction effect when it actually exists? The impact is that the ANCOVA
estimator may be inefficient; in fact, Freedman (2008) gave examples in which the ANCOVA
estimator is even less efficient than the benchmark ANOVA estimator.
To better adjust for X, we consider an alternative working model for ANCOVA that
includes the treatment-by-covariate interactions:
E(Yi | Ai, Xi) = ϑTAi +
k∑
t=1
β/Tt (Xi − µX)I(Ai = at), (3)
where ϑ, β/1, . . . , β/k are unknown vectors and I(·) is the indicator function. We call model (3)
the heterogeneous working model because it includes the interaction terms to accommodate
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the treatment effect heterogeneity across covariates, i.e., patients with different covariate
values may benefit differently from the treatment. By Lemma 2 in the supplementary




t (Xi − µX)I(Ai = at)}2 is minimized at (ϑ, β/1, ..., β/k) =




i ), i.e., ANCOVA with working model (3) is also
model-assisted.
To differentiate the methods based on (2) and (3), we refer to the method based on (2)
as ANCOVA and the one based on (3) as ANHECOVA.
As a final remark, both working models (2) and (3) use the centered covariate vector
X − µX . Otherwise, ANCOVA and ANHECOVA do not directly provide estimators of θ.
Centering is crucial, the only non-trivial exception is when homogeneous working model (2)
is used and linear contrast θt−θs is estimated, as the covariate mean µX cancels out. When
fitting the working models (2) and (3) with real datasets, we can use the least squares with
µX replaced by X¯, the sample mean of all Xi’s. In other words, we can center the baseline
covariates before fitting the models. Since this step introduces non-negligible variation to
the estimation, it affects the asymptotic variance of model-assisted estimator of θ and its
estimation for inference. Thus, we cannot assume the data has been centered in advance
and µX = 0 without loss of generality (see §3.4).
3 Methodology and Theory
3.1 Estimation
We first describe the estimators of θ under (1)-(3). The traditional ANOVA estimator is
θˆ
AN
= (Y¯1, ..., Y¯k)
T , (4)
where Y¯t is the sample mean of the responses Yi’s from patients under treatment t. As
n→∞, θˆ
AN
is consistent and asymptotically normal.
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Using the homogeneous working model (2), the ANCOVA estimator of θ is the least
squares estimator of the coefficient vector ϑ in the linear model (2) with (Ai, Xi) as regres-





Y¯1 − βˆT (X¯1 − X¯), ..., Y¯k − βˆT (X¯k − X¯)
)T
, (5)
where X¯t is the sample mean of Xi’s from patients under treatment t, X¯ is the sample












(Xi − X¯t)Yi (6)
is the least squares estimator of β/ in (2). It is shown in Theorems 1 and 3 that θˆ
ANC
is
consistent and asymptotically normal as n → ∞ regardless of whether working model (2)
is correct or not, i.e., ANCOVA is model-assisted.
The term βˆT (X¯t − X¯) in (5) is an adjustment for covariate X applied to the ANOVA
estimator Y¯t. However, it may not be the best adjustment in order to reduce the variance.
A better choice is to use heterogeneous working model (3). The ANHECOVA estimator of












(Xi − X¯t)(Xi − X¯t)T
}−1 ∑
i:Ai=at
(Xi − X¯t)Yi (8)
is the least squares estimator of β/t in (3) for each t. It is shown in Theorems 1-3 below
that the ANHECOVA estimator θˆ
ANHC
is not only model-assisted, but also asymptotically




, regardless of whether model (3) is correct or not.
The following heuristics reveal why the adjustment βˆTt (X¯t − X¯) in (7) is better than
the adjustment βˆT (X¯t − X¯) in (5), and why ANHECOVA often gains but never hurts
efficiency even if model (3) is wrong. As the treatment has no effect on X, both X¯t and X¯
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estimate the same quantity and, hence, βˆTt (X¯t − X¯) is an “estimator” of zero. As n→∞,
βˆt converges to βt = Σ
−1
X cov(X, Y
(t)) in probability, regardless of whether (3) is correct or
not (Lemma 3 in the supplementary material). Hence, we can “replace” βˆTt (X¯t − X¯) by
βTt (X¯t − X¯). Under simple randomization,
var{Y¯t − βTt (X¯t − X¯)} = var(Y¯t) + var{βTt (X¯t − X¯)} − 2cov{Y¯t, βTt (X¯t − X¯)}
= var(Y¯t)− var{βTt (X¯t − X¯)}.
(9)
Consequently, Y¯t − βˆTt (X¯t − X¯) has a smaller asymptotic variance than Y¯t. Note that (9)
does not hold with βt replaced by other quantities. This explains why the adjustment
βˆT (X¯t − X¯) in ANCOVA may lose efficiency, as βˆ in (6) converges to pi1β1 + · · ·+ pikβk.
The variance reduction technique by (9) can be found in the generalized regression
(GREG) approach in the survey sampling literature (Cassel et al., 1976; Cochran, 1977;
Sa¨rndal et al., 2003; Fuller, 2009; Shao and Wang, 2014; Ta et al., 2020). From the theory
of GREG, βˆt in (7) may be replaced by any estimator that converges to βt in probability,
without affecting the asymptotic distribution of the GREG estimator. This motivates
the following potential improvement to (8), which utilizes the fact that X has the same







(Xi − X¯)(Xi − X¯)T
}−1 ∑
i:Ai=at
(Xi − X¯t)Yi, (10)
where nt is the number of units under treatment t. This alternative estimator alleviates
the concern of using an unstable inverse in (8) when the sample size is small.
3.2 Asymptotic theory under simple randomization
We consider asymptotic theory under simple randomization for a general class of estimators
of the form
θˆ( bˆ1, ..., bˆk) =
(




where bˆt’s have the same dimension as X and can either be fixed or depend on the trial
data. Note that class (11) contains all estimators we have discussed so far:




if bˆt = 0 for all t
θˆ
ANC
if bˆt = βˆ in (6) for all t
θˆ
ANHC
if bˆt = βˆt in (8) or (10) for all t
(12)
Theorem 1. Assume (C1) and simple randomization for treatment assignment.





θˆ( bˆ1, ..., bˆk)− θ
}
→ N (0, VSR(B)) in distribution (13)
where
VSR(B) = diag{pi−1t var(Y (t) − bTt X)}+BTΣXB +BTΣXB −BTΣXB,
diag(dt) denotes the k × k diagonal matrix with the tth diagonal element dt, B =
(β1, ..., βk), the matrix with columns β1, ..., βk, and B = (b1, ..., bk). In particular,






as described by (12).
(ii) (Optimality of ANHECOVA). VSR(B) is minimized at B = B in the sense that
VSR(B)− VSR(B) is positive semidefinite for all B.
We briefly describe the proof for part (ii) in Theorem 1 and defer other details to the
supplementary material. Notice that
VSR(B)− VSR(B) = diag{pi−1t (βt − bt)TΣX(βt − bt)} − (B −B)TΣX(B −B).




Lemma 1. Let M be a matrix whose columns are m1, ...,mk, and pi1, ..., pik be nonnegative
constants with
∑k




t mt)−MTM is positive semidefinite.
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We would like to emphasize that Theorem 1(i) holds regardless of whether model (3)
is correct or not. Theorem 1(ii) shows that ANHECOVA not only satisfies Principle 1
(guaranteed efficiency gain over ANOVA), but is also the most efficient estimator within
the class of estimators in (11) as it attains the optimal VSR(B). Another consequence
of Theorem 1(ii) is that adjusting for more covariates in ANHECOVA does not lose and
often gains asymptotic efficiency, although adjusting for fewer covariates may have better
performance when n is small.
For the important scenario of estimating the linear contrast θt − θs with fixed t and
s, the corresponding model-assisted estimator is cTtsθˆ, where θˆ is given by (11) and cts
is the k-dimensional vector whose tth component is 1, sth component is −1, and other
components are 0. The following corollary provides a direct comparison of the asymptotic
variances of ANOVA, ANCOVA, and ANHECOVA estimators of linear contracts, showing
that the ANHECOVA estimator has strictly smallest asymptotic variance except for some
very special cases.
Corollary 1. Assume (C1) and simple randomization.







(1− pit − pis)(βt − βs)TΣX(βt − βs)
pit + pis
,
which is always ≥ 0 with equality holds if and only if
pisβt + pitβs = 0 and (βt − βs)(1− pit − pis) = 0. (14)
(ii) The difference between the asymptotic variances of cTtsθˆANC and c
T
tsθˆANHC is
(βt − β)TΣX(βt − β)
pit
+
(βs − β)TΣX(βs − β)
pis
− (βt − βs)TΣX(βt − βs),




and (βt − βs)(1− pit − pis) = 0. (15)
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When k = 2, i.e., there are only two arms, (14) reduces to pi2β1+pi1β2 = 0; (15) reduces
to β1 = β2 or pi1 = pi2 = 1/2. The same conclusions were also obtained by Lin (2013) under
a different framework that only considers the randomness in the treatment assignments.
Liu and Yang (2020) extended the results in Lin (2013) to stratified simple randomization.
We would like to emphasize that when there are more than two arms (k > 2), (14)
or (15) only holds in denegerate or peculiar cases. For the comparison of ANHECOVA
with ANOVA, (14) holds if and only if βt = βs = 0, because 0 < pit + pis < 1 when
k > 2. For the comparison of ANHECOVA with ANCOVA, (15) holds if and only if
βt = βs = β =
∑k
t=1 pitβt. Therefore, βt = βs is not enough for ANCOVA to be as efficient
as ANHECOVA for estimating θt − θs. Moreover, even if treatment allocation is balanced,
i.e., pi1 = · · · = pik, ANCOVA is generally less efficient than ANHECOVA when there are
more than two arms; this is different from the conclusion in the case of two arms. Finally,
in estimating θt − θs for all pairs of t and s, for ANOVA to have the same asymptotic
efficiency as ANHECOVA, all βt’s need to be zero, i.e., X is uncorrelated with Y
(t) for
every t; for ANCOVA to have the same asymptotic efficiency as ANHECOVA, all βt’s must
be the same, i.e., models (2) and (3) are the same.
It is worth to mention that when there are more than two treatment arms, the ANCOVA
estimator can be either more efficient or less efficient than the ANOVA estimator even under
balanced treatment allocation. This is also observed by Freedman (2008) in some specific
examples.
3.3 Asymptotic theory under covariate-adaptive randomization
We now consider the estimation of θ under covariate-adaptive randomization as described
in §2.2. Specifically, we would like to provide answers to the following questions: Is there an
estimator whose asymptotic distribution is invariant with respect to different randomization
schemes, to attain the validity and universality principle? Is there an estimator that is
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asymptotically most efficient within the class of estimators of form (11) under any covariate-
adaptive randomization?
The answers to these two questions are affirmative, as established formally in Theorems
2 and 3, respectively. Importantly, the key to achieve the validity and universality principle
as well as guaranteed efficiency gain is using the ANHECOVA θˆ
ANHC
in (7) with all the joint
levels of Z included in the covariate X.
Theorem 2. (Validity and Universality of ANHECOVA). Assume (C1) and (C2). If
heterogeneous model (3) is used with X containing the dummy variables for all the joint
levels of Z as a sub-vector, then, regardless of whether working model (3) is correct or not








→ N(0, VSR(B)) in distribution, (16)
where VSR(B) = diag{pi−1t var(Y (t) − βTt X)}+BTΣXB and B = (β1, ..., βk).
Comparing Theorem 1 with Theorem 2, we see that the ANHECOVA estimator includ-
ing all dummy variables for Z has exactly the same asymptotic variance in simple random-
ization and any covariate-adaptive randomization satisfying (C2), which is reflected by the
fact that VSR(B) is the same as VSR(B) in (13) with B = B. Therefore, this estimator
fulfills Principle 2 (validity and universality) so that the same inference procedure can be
used regardless of which randomization scheme is used. As we show next, however, this
is not true for ANOVA or ANCOVA using model (2), or for ANHECOVA when Z is not
fully included in the working model.
To answer the second question, we need a further condition on the randomization
scheme, mainly for estimators not using model (3) or not including all levels of Z in X.






− pi1, . . . , nk(z)n(z) − pik, z ∈ Z
)T
| Z1, . . . , Zn → N (0, D) in distribution,
where D is a block diagonal matrix whose blocks are matrices Ω(z)/P (Zi = z), z ∈ Z.
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Condition (C3) weakens Assumption 4.1(c) in Bugni et al. (2019), where Ω(z) takes
a more special form. For simple randomization, Ω(z) = diag(pit) − pipiT for all z, where
pi = (pi1, . . . , pik)
T . For stratified permuted block randomization and stratified biased coin
randomization, Ω(z) = 0 for all z. Note that Pocock-Simon’s minimization scheme does not
satisfy (C3) because the treatment assignments are correlated across strata, despite some
recent theoretical result has been obtained (Hu and Zhang, 2020). Thus, the following
result does not apply to minimization. However, as our Theorem 2 does not require (C3),
it applies to minimization.
The next theorem establishes the asymptotic distribution of the class (11) of estima-
tors under covariate-adaptive randomization, based on which we show the optimality of
ANHECOVA.
Theorem 3. Assume (C1), (C2), and (C3). Consider class (11) of estimators and, without
loss of generality, we assume that all levels of Z are included in X, as the components of
bˆt’s in (11) corresponding to levels of Z not in X may be 0.




θˆ( bˆ1, ..., bˆk)− θ
}
→ N(0, V (B)) in distribution, (17)
where
V (B) = VSR(B)− E [R(B){ΩSR − Ω(Zi)}R(B)}] , (18)
VSR(B) is given in (13), B = (b1, ..., bk), ΩSR = diag(pit) − pipiT , and R(B) =
diag
(
pi−1t E{Y (t)i − θt − bTt (Xi − µX) | Zi}
)
. Furthermore, R(B) = 0 and, hence,
V (B) = VSR(B), where B = (β1, ..., βk).
(ii) (Optimality of ANHECOVA). V (B) is minimized at B = B in the sense that V (B)−
V (B) is positive semidefinite for all B.
The main technical challenge in the proof of Theorem 2 and Theorem 3 is that the
treatment assignments A1, . . . , An are not independent, so we cannot directly apply the
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classical Linderberg central limit theorem. Instead, we decompose θˆ( bˆ1, ..., bˆk) − θ into
four terms and then apply a conditional version of the Linderberg central limit theorem to
handle the dependence. The details can be found in the supplementary material.
A number of conclusions can be made from Theorem 3.
1. While Theorem 2 answers the first question in the beginning of §3.3, i.e., θˆ
ANHC
with all
joint levels of Z included in model (3) achieves Principle 2 (validity and universality),
the second question is answered by Theorem 3(ii) showing that θˆ
ANHC
also attains
Principle 1 (guaranteed efficiency gain); in fact, it is asymptotically the most efficient
estimator compared with all estimators in class (11).
2. A price paid for not using model (3) or not including all levels of Z in (3) is that the
asymptotic validity of the resulting estimator requires condition (C3), which is not
needed in Theorem 2. Furthermore, the resulting estimator not only is less efficient
according to the previous conclusion, but also has a more complicated asymptotic
covariance matrix depending on the randomization schemes (universality is not sat-
isfied), which requires extra handling in variance estimation for inference; see, for
example, Shao et al. (2010) and Bugni et al. (2018).
3. Under covariate-adaptive randomization satisfying (C2)-(C3), it is still true that the
ANCOVA estimator using model (2) may be asymptotically more efficient or less
efficient than the benchmark ANOVA estimator.
4. From (18), the asymptotic covariance matrix V (B) is invariant with respect to ran-
domization scheme if R(B) in (18) is 0, which is the case when B = B, i.e., θˆ
ANHC
is
used with all levels of Z included in X. If R(B) is not 0, such as the case of ANOVA,
ANCOVA, or ANHECOVA not adjusting for all joint levels of Z, then V (B) depends
on randomization scheme and, the smaller the Ω(z), the more efficient the estimator
is. Thus, the stratified permuted block or biased coin with Ω(z) = 0 for all z is
preferred in this regard.
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5. The roles played by design and modeling can be understood through
V (B)− VSR(0) = {VSR(B)− VSR(0)} − E [R(B){ΩSR − Ω(Zi)}R(B)}] ,
where VSR(0) is the asymptotic variance of ANOVA estimator under simple random-
ization. As we vary the randomization scheme and the working model, the change in
the asymptotic variance is determined by two terms. The first term {VSR(B)−VSR(0)}
arises from using a working model; the second term E [R(B){ΩSR − Ω(Zi)}R(B)] is
the reduction due to using a covariate-adaptive randomization scheme, and the re-
duction also depends on the working model being used via R(B).
The last conclusion from Theorem 3 requires a further derivation, which leads to the fol-
lowing corollary.
Corollary 2. Assume (C1)-(C3) and that X only includes the dummy variables for all
joint levels of Z. Then, for any B in (17), V (B) = VSR(B) + E{R(B)Ω(Zi)R(B)}.
A direct consequence from Corollary 2 is that, if Ω(z) = 0 for all z (e.g., stratified
permuted block or biased coin randomization is used) and X only includes all joint levels
of Z, then all estimators in class (11), including the benchmark ANOVA estimator, have
the same asymptotic efficiency as the ANHECOVA estimator under any randomization. In
other words, modeling with all joint levels of Z is equivalent to designing with Z.
3.4 Variance estimation and the robust standard error principle
For inference on a function of θ based on Theorems 1 to 3, a crucial step is to construct
a consistent estimator of asymptotic variance. For ANOVA or ANCOVA, the customary
linear model-based variance estimation assuming homoscedasticity can be inconsistent, as
criticized by Freedman (2008). This motivates Principle 3—robust standard error. That
is, we should use variance estimators that are consistent regardless of whether the working
model is correct or not and whether heterpscedaticity is present or not.
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Consider the ANHECOVA estimator θˆ
ANHC
in (7) (using either (8) or (10)), where the
adjustment covariates X include all dummy variables for Z that is used in the random-
ization. There exist formulas for heteroscedaticity-robust standard error (such as those
provided in the sandwich package in R). However, those formulas cannot be directly ap-
plied here, because they do not account for the additional variation introduced by centering
the covariate X as required by the identification of θ. In fact, the term BTΣXB in the
asymptotic variance VSR(B) in Theorem 2 arises from centering X.
Instead, we should use the robust variance estimator based on VSR(B), as described
next. Let ΣˆX be the sample covariance matrix of Xi based on the entire sample and S
2
t (βˆt)
be the sample variance of (Yi − βˆTt Xi)’s based on the patients in treatment arm t. Then
VSR(B) in (16) can be estimated by
Vˆ = diag(pi−1t S
2
t (βˆt)) + Bˆ
T ΣˆXBˆ. (19)
This variance estimator is consistent as n → ∞ regardless of whether the heterogeneous
working model (3) or homoscedaticity (i.e., var(Y
(t)
i − βtXi | Xi) is a constant) holds or
not, and regardless of which randomization scheme is used.
In most applications the primary analysis is about treatment effects in terms of the
linear contrast θt − θs = cTtsθ for one or several pairs of (t, s). For large n, an asymptotic
level (1− α) confidence interval of θt − θs is(
cTtsθˆANHC − zα/2SEts, cTtsθˆANHC + zα/2SEts
)
,








s (βˆs) + (βˆt− βˆs)T ΣˆX(βˆt− βˆs) and zα is the (1−α) quantile
of the standard normal distribution. The same form of confidence interval can be used for





and SE2c = c
T Vˆ c, respectively. Let C be the collection of all linear contrasts
with dimension k. An asymptotic level (1−α) simultaneous confidence band of cT θ, c ∈ C ,
can be obtained by Scheffe´’s method,(
cT θˆ
ANHC
− χα,k−1 SEc, cT θˆANHC + χα,k−1 SEc
)
, c ∈ C ,
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where χ2α,k−1 is the (1 − α) quantile of the chi-square distribution with (k − 1) degrees of
freedom. Correspondingly, to test the hypothesis that all θt’s are the same, i.e., H0 : θ1 =
· · · = θk, an asymptotic level α chi-square test rejects H0 if and only if
θˆT
ANHC
CT (CVˆ CT )−1Cθˆ
ANHC
> χ2α,k−1,
where C is the (k − 1)× k matrix whose tth row is cTtk, t = 1, ..., k − 1.
Inference procedures based on the ANOVA or ANCOVA estimator can be similarly
obtained using Theorems 1 and 3. However, as they do not satisfy the validity and uni-
versality principle, special treatment is needed for each covariate-adaptive randomization
scheme. For example, under the stratified permuted block or biased coin randomization,
the ANOVA or ANCOVA estimator is asymptotically more efficient than the same estima-
tor under simple randomization; thus, using variance estimators valid only under simple
randomization may lead to conservative inference. To eliminate the conservativeness, mod-
ifications depending on covariate-adaptive randomization schemes have to be made (Shao
et al., 2010; Bugni et al., 2018). This is another reason why we recommend ANHECOVA
over the other model-assisted estimators for the practice.
4 Empirical Results
4.1 Simulation results
We perform a simulation study based on the placebo arm of 481 patients in a real clinical
trial to demonstrate the finite-sample properties of the model-assisted procedures. We use
the observed continuous response of these 481 patients as the potential response Y (1) under
treatment arm 1, and a 2-dimensional continuous baseline covariate (U,W ). The empirical
distribution of (Y (1), U,W ) of these patients is the population distribution in simulations.
Notice that we do not know the true relationship between Y (1) and (U,W ) because they
are from the real data. Thus, the working models (2) and (3) may be misspecified.
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In all numerical results, we apply (10) for ANHECOVA.
We consider three simulation studies that differ in how the potential responses Y (2) and
Y (3) of the other two treatment arms are generated, and how the treatment assignment
is randomized. Our first simulation compares the standard deviations of the ANOVA,
ANCOVA, and ANHECOVA estimators of θ2 − θ1, with X = U for ANCOVA and AN-
HECOVA. The two additional potential responses are generated according to
Y (2) = Y (1) + ζ(U − µU), (so θ2 = θ1),
Y (3) = Y (2), (so θ3 = θ1),
(20)
and with sample size 481 (all data points) and treatment being assigned by simple random-
ization with three different allocation proportions: 1:2:2, 1:1:1, and 2:1:1. Thus, the only
randomness in the first simulation study is from treatment assignments. Here µU is the
mean of 481 U -values and ζ ranges from −1 to 1 with ζ = 0 corresponds to β1 = β2 = β3.
Although we only consider the estimation of θ2 − θ1, data from the third arm is still used
by ANCOVA and ANHECOVA.
Based on 10,000 simulations, all three estimators have negligible biases and their stan-
dard deviations are plotted for different values of ζ in Figure 1. The simulation result shows
that, as predicted by our theory, ANHECOVA is generally more efficient than the other
two estimators, except when ζ is nearly 0 where ANCOVA is comparable to ANHECOVA.
Furthermore, the simulation with the 1:2:2 allocation (left panel in Figure 1) shows very
clearly that there is no definite ordering of the variances of ANCOVA and ANCOVA. Our
Corollary 1 suggests that a balanced allocation does not guarantee the superiority of AN-
COVA over ANOVA when there are multiple arms (in contrast with the case of two arms),
which can be seen from the simulations with 1:1:1 allocation (middle panel in Figure 1).
The second and third simulation studies are intended to examine the performance of
standard errors and the coverage of proposed 95% asymptotic confidence intervals for θ2−θ1
and θ3 − θ1. In the second simulation study, treatment assignments are still generated by
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simple randomization (with allocation 1:1:1 or 1:2:2), but a random sample of size n = 200
or 400 is drawn from the 481 subjects with replacement. The setup (20) is also changed to
Y (2) = −1.3 + Y (1) − 0.8(U − µU), (so θ2 − θ1 = −1.3),
Y (3) = −1 + Y (1), (so θ3 − θ1 = −1).
(21)
For both ANCOVA and ANHECOVA, we include U but not W in their working models,
so X = U . The simulation results based on 10,000 simulations are shown in Table 1.
In the third simulation study, the treatment assignments are generated by stratified
permuted block randomization with block size 6 and treatment allocation 1:1:1 or block
size 10 and treatment allocation 1:2:2. The covariate Z used in randomization is a three-
level discretized W . Similar to the second simulation study, a random sample of size
n = 200 or 400 is drawn, but the setup (21) is changed to
Y (2) = −1.3 + Y (1) − 0.5(U − µU) + 0.3(W − µW ), (so θ2 − θ1 = −1.3),
Y (3) = −1 + Y (1) − 0.1(U − µU)− 0.1(W − µW ), (so θ3 − θ1 = −1),
(22)
where µW is the mean of all 481 W -values. For ANCOVA and ANHECOVA, we consider
two working models with different choices of X. One model includes the dummy variables
for Z and U but not W , motivated by the fact that Z is a discretization of W and carries
some information from W . The other model includes the dummy variables for Z, U , and
W (this is different from just including U and W because W is continuous and the working
model is linear). The simulation results based on 10,000 simulations are shown in Table 2.
Notice that in the third simulation that uses a covariate-adaptive randomization scheme,
consistent standard errors for ANOVA or ANCOVA can be obtained using Theorem 3 but
they are not readily available. For this reason, in the third simulation we use the standard
error derived under simple randomization based on Theorem 1. In other words, standard
errors for each estimator are computed using the same formula in the second and third
simulation studies. Based on our theory, it is expected that confidence intervals based on
ANOVA and ANCOVA are conservative.
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The following is a summary of the simulation results in Tables 1-2.
1. All estimators have negligible bias compared to their standard deviation.
2. ANHECOVA has the smallest standard deviation in all our simulation settings. This
is consistent with our asymptotic theory.
3. There is no unambiguous ordering of the standard deviations of ANCOVA and AN-
COVA. In particular, in the third simulation study (Table 2), ANCOVA adjusting
for Z,U,W is better in estimating θ2 − θ1 but worse in estimating θ3 − θ1. A simi-
lar observation can also be obtained from Table 1. Moreover, in Table 1, ANCOVA
has larger standard deviations compared with ANOVA in estimating θ3− θ1, despite
β3 = β1, which is contrary to the results under two arms.
4. In the third simulation study that uses stratified permuted block randomization (Ta-
ble 2), including the additional covariate W in the working model results in a smaller
standard deviation for ANHECOVA in all our simulation settings. Interestingly, this
is not always the case for ANCOVA.
5. In the second simulation study that uses simple randomization (Table 1), the robust
standard errors for all the model-assisted estimators are very close to their actual
standard deviations, and confidence intervals have the nominal coverage in all set-
tings. However, although this is still true for ANHECOVA in the third simulation
study under covariate-adaptive randomization (Table 2), it is not the case for ANOVA
and ANCOVA, i.e., standard errors valid under simple randomization appear to over-
estimate the actual standard deviations, so the confidence intervals are conservative.
4.2 A real data example
We further illustrate the different model-assisted procedures using a real data example.
Chong et al. (2016) conducted a randomized experiment to evaluate the impact of low
dietary iron intake on human capital attainment. They recruited students of age 11 to 19
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in a rural area of Cajamarca, Peru, where many adolescents suffer from iron deficiency. The
goal of this randomized trial is to quantify the causal effect of reduced adolescent anemia
on school attainment. By using students’ school grade as covariate Z with five levels, a
stratified permuted block randomization with 1:1:1 allocation was applied to assign 219
students to one of the following three promotional videos:
Video 1: A popular soccer player is encouraging iron supplements to maximize energy;
Video 2: A physician is encouraging iron supplements for overall health;
Video 3: A dentist encouraging oral hygiene without mentioning iron at all.
Chong et al. (2016) investigated whether showing different promotional videos to the stu-
dents can improve their academic performance through increased iron intake. Video 3 is
treated as a “placebo”. After the treatment assignments, four students were excluded from
the analysis for various reasons, which we also ignore in our analysis. The dataset is avail-
able at https://www.openicpsr.org/openicpsr/project/113624/version/V1/view.
Chong et al. (2016) used various outcomes in their analysis; here we focus on one of
their primary outcomes—the academic achievement—as an example. In this trial, the
academic achievement is measured by a standardized average of the student’s grades in
math, foreign language, social sciences, science, and communications in a semester. For
the model-assisted approaches, we use the baseline anemia status as the covariate in our
working models (2) and (3), which is believed to moderate the treatment effect (Chong
et al., 2016).
Table 3 reports the analysis results by using different model-assisted procedures. Like in
our simulation studies, the standard errors for ANOVA and ANCOVA are computed using
estimator based on Theorem 1 for simple randomization, even though the randomization
scheme here is covariate-adaptive. All the model-assisted estimators find similar effect sizes
for the two contrasts (physician versus placebo, soccer star versus placebo), and the two
ANHECOVA estimators have slightly smaller standard errors. Including baseline anemia
25
status in the working model are useful to reduce the standard error. Compared to the
placebo, the promotional video by the soccer player does not seem to have a positive
effect on the academic achievement. In contrast, the video of the physician promoting iron
supplements appears to have a positive effect. The difference between ANHECOVA and
ANOVA or ANCOVA, and between including and not including anemia can be seen from
the magnitude of the corresponding p-values.
5 Recommendation and Discussion
To improve its credibility and efficiency, we believe a clinical trial analysis can benefit from
Principles 1 to 3 outlined in §1 and discussed throughout §2-3.
Our theoretical investigation shows that the only method that satisfies all the three
principles is the ANHECOVA with all joint levels of Z included in heterogeneous working
model (3), coupled with the robust variance estimator given by (19). Thus we believe
it deserves wider usage in the clinical trial practice. Our theory shows that using any
other estimator with the form (11), including ANOVA, ANCOVA using model (2), and
ANHECOVA not adjusting for all joint levels of Z, suffers from invalidity, inefficiency, or
non-universality in the sense that the asymptotic distribution of the estimator depends on
a particular randomization scheme.
Our model-assisted asymptotic theory is given in terms of the joint asymptotic dis-
tribution in estimating θ, the vector of mean responses, with multiple treatment arms
randomized with a wide range of covariate-adaptive randomization schemes. It can be
readily used for inference about linear or nonlinear functions of θ, with either continuous
or discrete responses. Although working models (2) and (3) are not commonly used for dis-
crete responses, ANHECOVA is still asymptotically valid as it is model-assisted. For binary
responses, a popular model is logistic regression. However, if X has a continuous compo-
nent, the standard logistic regression inference is model-based instead of model-assisted
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and, thus, it may be invalid if the logistic model is not correctly specified.
In applications, one may be interested in comparing just two treatments, although the
trial contains more than two treatment arms. A simple way of analysis is to ignore the
data from other arms and apply inference procedures to the two arms of interest. For
ANOVA, this is equivalent to using all the arms, since ANOVA does not borrow strength
from other arms through using covariates. However, using data from two arms only is
not recommended when ANHECOVA is applied, because it can utilize covariate data from
other arms to gain efficiency. Regarding ANCOVA, there is no definite order of efficiency
for using the whole dataset or data from two given arms, since using more covariate data
in ANCOVA may increase or decrease efficiency.
Our Theorem 2 can also be applied to rerandomization schemes (Li et al., 2018; Li and
Ding, 2020) using discrete covariates. Rerandomization also tries to balance the treatment
assignments across levels of Z, but it randomizes the treatment assignments for all patients
simultaneously. This is different from the covariate-adaptive randomization schemes that
assign treatment sequentially. For two-armed trials, (Li et al., 2018, Corollaries 1 and
2) have shown that rerandomization satisfies (C2), but it is yet unknown if it satisfies
(C3). Similar results for model-assisted inference can also be found in (Li and Ding, 2020,
Theorem 3).
As a final cautionary note, standard software does not produce asymptotically valid
standard errors for model-assisted inference. We implement an R package called RobinCar
to compute the model-assisted estimators and their robust standard errors, that is available
at https://github.com/tye27/RobinCar.
SUPPLEMENTARY MATERIAL
The supplementary material contains all technical proofs.
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Figure 1: Standard deviations of ANOVA, ANCOVA, and ANHECOVA estimators based on
10,000 simulations
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Table 1: Bias, standard deviation (SD), average standard error (SE), and coverage probability
(CP) of 95% asymptotic confidence interval under simple randomization and setup (21) based on
10,000 simulations
θ2 − θ1 θ3 − θ1
Allocation n Method Bias SD SE CP Bias SD SE CP
1:1:1 400 ANOVA 0.001 0.162 0.162 0.950 -0.002 0.137 0.138 0.952
ANCOVA 0.000 0.143 0.143 0.951 -0.003 0.138 0.138 0.950
ANHECOVA 0.001 0.140 0.140 0.953 -0.002 0.134 0.134 0.950
200 ANOVA -0.001 0.229 0.229 0.947 0.001 0.195 0.195 0.950
ANCOVA 0.000 0.204 0.203 0.946 0.002 0.196 0.195 0.949
ANHECOVA 0.000 0.200 0.198 0.945 0.002 0.191 0.190 0.949
1:2:2 400 ANOVA 0.001 0.173 0.172 0.952 0.001 0.155 0.154 0.948
ANCOVA 0.001 0.159 0.158 0.951 0.001 0.157 0.156 0.947
ANHECOVA 0.001 0.156 0.155 0.948 0.000 0.152 0.150 0.946
200 ANOVA 0.001 0.245 0.244 0.946 0.004 0.219 0.218 0.946
ANCOVA 0.002 0.229 0.224 0.943 0.005 0.224 0.221 0.943
ANHECOVA 0.001 0.225 0.219 0.943 0.003 0.216 0.212 0.941
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Table 2: Bias, standard deviation (SD), average standard error (SE), and coverage probability
(CP) of 95% asymptotic confidence interval under stratified permuted block randomization (block
size = 6) and setup (22) based on 10,000 simulations
θ2 − θ1 θ3 − θ1
Allocation n Method X Bias SD SE CP Bias SD SE CP
1:1:1 400 ANOVA -0.002 0.258 0.333 0.986 -0.002 0.163 0.195 0.980
ANCOVA Z,U -0.003 0.259 0.305 0.977 -0.002 0.161 0.228 0.994
Z,U,W -0.017 0.246 0.292 0.977 0.003 0.178 0.239 0.989
ANHECOVA Z,U -0.004 0.258 0.257 0.949 -0.001 0.158 0.157 0.945
Z,U,W -0.031 0.234 0.234 0.946 0.010 0.154 0.153 0.943
200 ANOVA -0.004 0.364 0.471 0.987 -0.002 0.233 0.276 0.979
ANCOVA Z,U -0.006 0.366 0.431 0.974 -0.002 0.231 0.323 0.994
Z,U,W -0.036 0.349 0.411 0.971 0.008 0.257 0.337 0.989
ANHECOVA Z,U -0.009 0.364 0.363 0.944 -0.001 0.225 0.221 0.943
Z,U,W -0.067 0.335 0.339 0.941 0.020 0.221 0.218 0.944
1:2:2 400 ANOVA 0.002 0.260 0.317 0.981 -0.001 0.176 0.199 0.974
ANCOVA Z,U 0.001 0.260 0.294 0.969 -0.001 0.175 0.244 0.994
Z,U,W -0.014 0.253 0.284 0.970 0.004 0.196 0.258 0.992
ANHECOVA Z,U -0.001 0.258 0.259 0.945 -0.002 0.171 0.169 0.947
Z,U,W -0.025 0.242 0.240 0.943 0.005 0.168 0.165 0.946
200 ANOVA -0.001 0.369 0.447 0.981 0.004 0.248 0.282 0.973
ANCOVA Z,U -0.003 0.370 0.415 0.971 0.005 0.248 0.345 0.994
Z,U,W -0.031 0.360 0.400 0.970 0.016 0.279 0.364 0.990
ANHECOVA Z,U -0.006 0.367 0.364 0.946 0.005 0.242 0.237 0.946
Z,U,W -0.050 0.344 0.343 0.943 0.017 0.239 0.233 0.943
Table 3: Estimate, standard error (SE), and p-value in the real data example analysis
Physician versus placebo Soccer star versus placebo
Method X Estimate SE p-value Estimate SE p-value
ANOVA 0.386 0.211 0.067 -0.068 0.205 0.739
ANCOVA Grade 0.403 0.203 0.046 -0.052 0.203 0.799
Grade, Anemia status 0.437 0.199 0.028 -0.085 0.201 0.672
ANHECOVA Grade 0.409 0.200 0.041 -0.051 0.201 0.800
Grade, Anemia status 0.481 0.193 0.013 -0.046 0.195 0.815
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Supplementary Material: Principles for
Covariate Adjustment in Analyzing
Randomized Clinical Trials
1 More Technical Details
Lemma 2. Let (C1) and (C2) be given and suppose P (Ai = at | Z1, . . . , Zn) = pit for all
t = 1, . . . , k and i = 1, . . . , n.
(i) For any integrable function f , we have that
E{f(Y (t)i , Xi)} = E(f(Yi, Xi) | Ai = at), and
E{f(Y (t)i , Xi) | Xi} = E(f(Yi, Xi) | Xi, Ai = at).
(ii) Let θ = (E(Y (1), ..., E(Y (k)))> be the potential response mean vector, β =
∑k
t=1 pitβt,




i ), t = 1, ..., k, then




Yi − ϑ>Ai − β/>(Xi − µX)
}2]
, and
(θ, β1, . . . , βk) = arg min
(ϑ,β/1,...,β/k)
E
{Yi − ϑ>Ai − k∑
t=1
β/>t (Xi − µX)I(Ai = at)
}2 .
The condition P (Ai = at | Z1, . . . , Zn) = pit for all t and i holds for most covariate-
adaptive randomization schemes. Note that it does not exclude the possibility that the set
of random variables {Ai, i = 1, . . . , n} is dependent on {Zi, i = 1, . . . , n}, which is indeed
the case for covariate-adaptive randomization schemes. We impose this condition only in
Lemma 2 to facilitate understanding the working models. This additional assumption is
not needed for our asymptotic theory in Section 3, as condition (C2) (ii) is sufficient.
Proof. (i) We focus on proving the second result; the first result can be shown similarly. For
simple randomization, this result immediately follows (C2) (i) as (Y
(1)
i , . . . , Y
(k)
i , Xi, Ai) are
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independent and identically distributed. For covariate-adaptive randomization, we remark
that the property of conditional independence (Dawid, 1979, Lemma 4.3), (C2) (i) and
the third condition in Lemma 2 imply that Ai is independent of {(Y (1)i , ..., Y (k)i , Xi, Zi), i =
1, . . . , n}. Then, it can be shown that
E{f(Yi, Xi) | Xi, Ai = at}












E{f(Y (t)i , Xi) | Xi, Z1 = z1, . . . , Zn = zn}P (Z1 = z1, . . . , Zn = zn | Xi)
=E{f(Y (t)i , Xi) | Xi}.
In the equalities above, we have used, respectively, the consistency of potential responses,
the law of iterated expectation, (C2) (i), and the remark above.
(ii) We only prove the first result. The second result can be proved similarly. Notice
that (θ, β) satisfies the following estimation equations:
E
[
I(Ai = at){Yi − θ>Ai − β>(Xi − µX)}
]
= 0, for any t (S1)
E
[
(Xi − µX){Yi − θ>Ai − β>(Xi − µX)}
]
= 0. (S2)
From Lemma 2, (S1) implies that for any t,
E
[










i − θt] = 0,
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and thus, θt = E(Y
(t)
i ). Then (S2) implies that
0 =E
[







































i )pit − ΣXβ







Lemma 3. Under conditions (C1)-(C2), βˆt = βt + op(1), t = 1, . . . , k, and βˆ = β + op(1).












































where the second line is because E(XiY
(t)
i | A,F) = E(XiY (t)i | F) = E(XiY (t)i | Zi)
from (C1) and (C2) (i). Moreover, n−1
∑n
i=1 I(Ai = at)XiY
(t)
i becomes an average of
independent random variables once conditional on {A,F}. From the existence of second
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moment of XY (t), and the weak law of large numbers for independent random variables,














∣∣∣∣ ≥  | A,F
)
= 0




























I(Zi = z)I(Ai = at)E(XiY
(t)








i | Zi = z)
n∑
i=1
























i | Zi = z)pitP (Zi = z) + op(1)
= pitE(XiY
(t)
i ) + op(1)









I(Ai = at)XiYi = E(XiY
(t)
i ) + op(1)
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I(Ai = at)Yi = E(Y
(t)
i ) + op(1)





{Xi − X¯t}{Xi − X¯t}> = ΣX + op(1).
The proof is completed by using the definition of βt.
2 Technical Proofs
2.1 Proof of (9)
Under simple randomization, A = (A1, . . . , An) are independent with other variables. We
decompose























where X¯−t = (n− nt)−1
∑
i:Ai 6=at Xi.
First, we show that X¯t and X¯−t are uncorrelated conditional on A, from






I(Ai = at)I(Aj 6= at)cov(Xi, Xj | A) = 0
where the last equality is from cov(Xi, Xj | A) = cov(Xi, Xj) = 0 for i 6= j. Similarly, we
can show that Y¯t and X¯−t are uncorrelated conditional on A.
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Then,























































































where the second equality is from cov(X¯−t, Y¯t | A) = 0, E(Y¯t | A) = E(Y (t)) and the
identity that cov(X, Y ) = E{cov(X, Y | Z)}+ cov{E(X | Z), E(Y | Z)}.
Also note that








































where the second equality uses the identity that var(X) = E{var(X | Z)}+var{E(X | Z)},
and E
(
X¯t − X¯−t | A
)
= E(Xi)− E(Xi) = 0.
2.2 Proof of Lemma 1























= tr{E(QQ>)} − tr{E(Q)E(Q>)}
≥ 0,
where tr denotes the trace of a matrix, Q denotes a p-dimensional random vector that takes
value pi−1t `tmt with probability pit, t = 1, . . . , k, and the last equality follows from the fact
that the covariance matrix var(Q) = E(QQ>)− E(Q)E(Q>) is positive semidefinite.
2.3 Proof of Theorem 1
(i) First, from X¯t − X¯ = Op(n−1/2) and bˆt = bt + op(1), we have
θˆ(bˆ1, . . . , bˆk) = θˆ(b1, . . . , bk) + {(X¯1 − X¯)(b1 − bˆ1), . . . , (X¯1 − X¯)(bk − bˆk)}>
= θˆ(b1, . . . , bk) + op(n
−1/2)
Then, we decompose θˆ(b1, . . . , bk) as
θˆ(b1, . . . , bk)− θ =

Y¯1 − θ1 − (X¯1 − µX)>b1
· · ·













and we analyze the two terms separately.
Consider M1, where the tth term equals




Yi − θt − (Xi − µX)>bt
We have E(M1t | A) = 0 and
var(M1t | A) = n−1t var{Y (t) − (X − µX)>bt} = (npit)−1var{Y (t) −X>bt}+ op(n−1),
and cov(M1t,M1s | A) = 0 for t 6= s, where A = {A1, . . . , An}. Hence, var(M1 | A) is a
diagonal matrix, with the diagonal elements being var(M1t | A), t = 1, . . . , k. From the
central limit theorem, we have that as n→∞,
M1√
var(M1 | A)
| A d−→ N(0, 1)








d−→ N(0, diag{pi−1t var(Y (t) −X>bt)})



















Finally, consider cov(M1,M2), where the (t, s) element equals
cov{Y¯t − θt − (X¯t − µX)>bt, (X¯ − µX)>bs}
= E
{












































where the first equality is from E{(Y¯t− θt− (X¯t−µX)>bt | A} = E{(X¯−µX)>bs | A} = 0.
Thus, ncov(M1,M2) = (B −B)>ΣXB and ncov(M2,M1) = B>ΣX(B −B).
Combining the above results, we conclude that
√
n{θˆ(b1, . . . , bk)− θ} is asymptotically
normal with mean 0 and variance VSR(B),
VSR(B) = diag{pi−1t var(Y (t) −X>bt)}+ (B −B)>ΣXB +B>ΣX(B −B) +B>ΣXB
= diag{pi−1t var(Y (t) −X>bt)}+B>ΣXB +B>ΣXB −B>ΣXB
(ii) Note that
VSR(B)− VSR(B)
= diag{pi−1t var(Y (t) − b>t X)} − diag{pi−1t var(Y (t) − β>t X)} − (B −B)>ΣX(B −B)
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Because
var(Y (t) − b>t X) = var(Y (t) − β>t X + β>t X − b>t X)
= var{Y (t) − β>t X}+ var{(βt − bt)>X}+ 2cov{Y (t) − β>t X, (βt − bt)>X}
= var{Y (t) − β>t X}+ (βt − bt)>ΣX(βt − bt)
Thus, we have
VSR(B)− VSR(B) = diag{pi−1t (βt − bt)>ΣX(βt − bt)} − (B −B)>ΣX(B −B).
The rest follows from applying Lemma 1 with M = Σ
1/2
X (B −B).
2.4 Proof of Corollary 1
































The results in Corollary 1 (i) follows from
σ2A − σ2U
=
β>t ΣXβt − 2cov(X>βt, Y (t))
pit
+
β>s ΣXβs − 2cov(X>βs, Y (s))
pis
+ {βt − βs}>ΣX{βt − βs}
=
β>t ΣXβt − 2β>t ΣXβt
pit
+
β>s ΣXβs − 2β>s ΣXβs
pis









+ {βt − βs}>ΣX{βt − βs}
= − {pisβt + pitβs}
>ΣX{pisβt + pitβs}
pitpis(pit + pis)
− {βt − βs}>ΣX{βt − βs}
(




where the second equality follows from βt = Σ
−1
X cov(X, Y
(t)). This also proves that σ2A ≤
σ2U , because ΣX is positive definite and pit + pis ≤ 1. If σ2A = σ2U , then we must have
pisβt + pitβs = 0 and (1− pit − pis){βt − βs} = 0.
To show the results in Corollary 1 (ii), notice that
σ2B =
var{Y (t) −X>βt +X>βt −X>β}
pit
+
var{Y (s) −X>βs +X>βs −X>β}
pis
=
var{Y (t) −X>βt}+ var{X>βt −X>β}
pit
+
var{Y (s) −X>βs}+ var{X>βs −X>β}
pis
where the second equality is because
cov{Y (t) − β>t X, β>t X − β>X} = cov{Y (t) − β>t X,X}{βt − β}
= {cov(Y (t), X)− β>t ΣX}{βt − β} = 0
Then,
σ2A − σ2B = {βt − βs}>ΣX{βt − βs} −
{βt − β}>ΣX{βt − β}
pit
− {βs − β}
>Σ{βs − β}
pis
In order to show that σ2A − σ2B ≤ 0, we prove a stronger statement: it is true that for
any β˜,
{βt − βs}>ΣX{βt − βs} − {βt − β˜}
>ΣX{βt − β˜}
pit




As a consequence, setting β˜ as β =
∑k
t=1 pitβt, the statement in (S3) also holds. This proves
σ2A − σ2B ≤ 0.











which equals zero when β˜ = {pisβt + pitβs}/(pit + pis). This is also the unique solution from
the positive definiteness of ΣX . It is also easy to see that the Hessian of the left hand side
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of (S3) is negative definite, which means that β˜ = {pisβt +pitβs}/(pit +pis) is the global and
unique maximizer of the left hand side of (S3). The statement in (S3) is true because when
evaluated at β˜ = {pisβt + pitβs}/(pit + pis), the left hand side of (S3) equals
{βt − βs}>ΣX{βt − βs}
−
{






















=− {βt(z)− βs(z)}>ΣX{βt(z)− βs(z)}
(




This completes the proof for σ2A ≤ σ2B, where the equality holds if and only if {βt−βs}(1−
pit − pis) = 0 and
∑k
t=1 pitβt = {pisβt + pitβs}/(pit + pis).
2.5 Proof of Theorem 2
We analyze the class of estimators of form (11) under covariate-adaptive randomization.
First, from X¯t − X¯ = Op(n−1/2) and bˆt = bt + op(1), we have
θˆ(bˆ1, . . . , bˆk) = θˆ(b1, . . . , bk) + {(X¯1 − X¯)(b1 − bˆ1), . . . , (X¯1 − X¯)(bk − bˆk)}>
= θˆ(b1, . . . , bk) + op(n
−1/2)
Then, we still decompose θˆ(b1, . . . , bk) as
θˆ(b1, . . . , bk)− θ =

Y¯1 − θ1 − (X¯1 − µX)>b1
· · ·













For M1, its tth term equals





















































































where the last equality is because nt/n = pit + op(1) and the remaining terms are shown in
the following to be Op(n
−1/2).
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Thus, the decomposition can be further refined as






























































First, consider C1. Let A = {A1, . . . , An} and F = {Z1, . . . , Zn}. Conditioned on A,F ,
the terms in C1t, the tth element in C1, are independently distributed. From (C2) (i), we
have E(C1t | A,F) = 0. From Lindeberg’s Central Limit Theorem, as n→∞,
C1t
var(C1t | A,F) | A,F
d−→ N(0, 1).









































































i − (Xi − µX)>bt | Zi
}]
+ op(1)
where the second line and the fifth line are respectively from (C2) (i) and (C2) (ii). Also,










i −X>i bt, Y (s)j −X>j bs | Zi, Zj
}
= 0













i − (Xi − µX)>bt | Zi
}]})
. (S5)














i − (Xi − µX)>βt | Zi
}]})
.




i ), we have
E
[




i )− cov(Xi, Y (t)i ) = 0.
Because Zi is discrete and Xi contains all joint levels of Zi as a sub-vector. According to
the estimation equations from the least squares, we have that
E
[
I(Zi = z){Y (t)i − θt − (Xi − µX)>βt | Zi}
]







i − θt − (Xi − µX)>βt | Zi
}
= 0, a.s.
Therefore, when X contains all joint levels of Z and bt = βt,
√
n(C2 + C3) = 0 a.s..
Consider M2, because M2 does not involve treatment indicators, so M2 follows the same




Finally, consider cov(C1,M2), whose (t, s) element equals
cov(C1t, (X¯ − µX)>βs) (S6)




















































































where the first equality is from E(C1t | A,F) = 0, the fourth equality is because cov(Y (t)i −
X>i βt, X
>
j βs | F) = 0 for i 6= j, the fifth equality is because E(Y (t)i −X>i βt | Zi) = θt−µ>Xβt





































i −X>i βt, X>i βs | Zi = z)
=o(n−1)
where the last equality is because nt(z)/n = P (Zi = z)pit + op(1) and that nt(z)/n is
bounded, hence, E{nt(z)}/n = P (Zi = z)pit + o(1).
In summary, we have shown that the asymptotic distribution of
√
n{θˆ(b1, . . . , bk)− θ}
is invariant under randomization schemes satisfying (C2), and satisfies
√
n{θˆ(b1, . . . , bk)− θ} =
√




























2.6 Proof of Theorem 3
(i) We decompose
√
n{θˆ(b1, . . . , bk) − θ} in the same way as in (S4), and the asymptotic
distribution of C1 is the same as (S5).
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From condition (C3), given F , √nC2 is asymptotically normal with mean zero. Let C2t





























i − θt − (Xi − µX)>bt | Zi = z
}]2






























































Moreover, because C3 only involves sums of identically and independently distributed









where pi = (pi1, . . . , pin)
>.
Therefore, we have that
√




pi−1t E{var(Y (t)i −X>i bt | Zi)}
}










In the following, we deal with the covariance between C1, C2, C3 and M2. Let M2s be
the sth element in M2, the covariance between C1t and M2s can be derived in a similar
fashion as in (S6) and, thus,




E{cov(Y (t)i −X>i bt, X>i bs | Zi)}+ o(n−1)
Then, we show that (C2,M2) converges in distribution to two independent random
variables. Denote C2 | F d−→ ξC , M2 d−→ ξM , where ξC is as defined in (S7). Note that
P (C2 ≤ t,M2 ≤ s)
= E{P (C2 ≤ t,M2 ≤ s | F)}
= E{P (C2 ≤ t | F)P (M2 ≤ s | F)} using (C2) (i)
= E [{P (C2 ≤ t | F)− P (ξC ≤ t)}P (M2 ≤ s | F)] + P (ξC ≤ t)P (M2 ≤ s)
→ P (ξC ≤ t)P (ξM ≤ s)



























































i − (Xi − µX)>bt | Zi
}
, E(X>i bs | Zi)
]
Hence,




i − (Xi − µX)>bt, X>i bs
]
+ o(1)
= {βt − bt}>ΣXbs + o(1).
Combining the above derivations, we conclude that
√
n(θˆ(b1, . . . , bk)− θ) is asymptotically
normal with mean 0 and variance
diag
{
pi−1t E{var(Y (t)i −X>i bt | Zi)}
}




+B>ΣXB + (B −B)>ΣXB +B>ΣX(B −B)
= diag
{
pi−1t E{var(Y (t)i −X>i bt | Zi)}
}








(t) − b>t X)



















R(B){diag(pit)− pipi> − Ω(Zi)}R(B)
]
= VSR(B)− E [R(B){ΩSR − Ω(Zi)}R(B)]
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i ), we have E[X
T
i {Y (t)i − θt − βTt (X −
µX)}] = cov(Xi, Y (t)i )− cov(Xi, Y (t)i ) = 0. Because Xi contains all dummy variables for the
joint levels of Zi, we have E{Y (t)i − θt − βTt (Xi − µX) | Zi} = 0. Hence R(B) = 0 and
R(B) = diag{pi−1t (βt − bt)TE(Xi − µX | Zi)}. Consequently, the difference in asymptotic
variance is
V (B)− V (B) = V (B)− VSR(B) = V (B)− VSR(B) + VSR(B)− VSR(B)
=diag{pi−1t (βt − bt)TΣX(βt − bt)} − (B −B)TΣX(B −B)− E [R(B){ΩSR − Ω(Zi)}R(B)}]
≥diag{pi−1t (βt − bt)TΣX(βt − bt)} − (B −B)TΣX(B −B)− E [R(B)ΩSRR(B)}]
=diag[pi−1t (βt − bt)TE{var(X | Z)}(βt − bt)]− (B −B)TE{var(X | Z)}(B −B),
where M ≥ M ′ means M −M ′ is positive semidefinite for two square matrices M and
M ′ of the same dimension, and the last line follows from ΩSR = diag(pit) − pipiT , the
expression for R(B), and the identity ΣX = E{var(X | Z)}+ var{E(X | Z)}. The positive
semidefiniteness of the right hand side is from applying Lemma 1 with M = [E{var(X |
Z)}]1/2(B −B).
2.7 Proof of Corollary 2
When X only contains the dummy variables for the joint levels of Z, R(B) = diag{pi−1t (βt−
bt)
T (Xi − µX)}. Then, it follows from the proof of Theorem 3 (ii) that
V (B)− VSR(B)
=diag{pi−1t (βt − bt)TΣX(βt − bt)} − (B −B)TΣX(B −B)− E [R(B)ΩSRR(B)}]
+ E [R(B)Ω(Zi)R(B)}]
=diag{pi−1t (βt − bt)TΣX(βt − bt)} − (B −B)TΣX(B −B)− E [R(B)diag(pit)R(B)}]
+ E
[
R(B)pipi>R(B)}]+ E [R(B)Ω(Zi)R(B)}]
=E[R(B)Ω(Zi)R(B)]
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